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ABSTRACT To ensure the safe and effective dosing of gentamicin in children, ther-
apeutic drug monitoring (TDM) is recommended. TDM utilizing Bayesian forecasting
software is recommended but is unavailable, as no population model that describes
the pharmacokinetics of gentamicin in pediatric oncology patients exists. This study
aimed to develop and externally evaluate a population pharmacokinetic model of
gentamicin to support personalized dosing in pediatric oncology patients. A nonlin-
ear mixed-effect population pharmacokinetic model was developed from retrospec-
tive data. Data were collected from 423 patients for model building and a further 52
patients for external evaluation. A two-compartment model with ﬁrst-order elimina-
tion best described the gentamicin disposition. The ﬁnal model included renal func-
tion (described by fat-free mass and postmenstrual age) and the serum creatinine
concentration as covariates inﬂuencing gentamicin clearance (CL). Final parameter
estimates were as follow CL, 5.77 liters/h/70 kg; central volume of distribution, 21.6
liters/70 kg; peripheral volume of distribution, 13.8 liters/70 kg; and intercompart-
mental clearance, 0.62 liter/h/70 kg. External evaluation suggested that current mod-
els developed in other pediatric cohorts may not be suitable for use in pediatric on-
cology patients, as they showed a tendency to overpredict the observations in this
population. The ﬁnal model developed in this study displayed good predictive per-
formance during external evaluation (root mean square error, 46.0%; mean relative
prediction error, 3.40%) and may therefore be useful for the personalization of
gentamicin dosing in this cohort. Further investigations should focus on evaluating
the clinical application of this model.
KEYWORDS pharmacokinetics, gentamicin, NONMEM, pediatrics, oncology,
pharmacometrics, population pharmacokinetics
Febrile neutropenia induced by chemotherapy is a common complication in pedi-atric oncology patients. Neutropenic patients are more susceptible to the develop-
ment of infections (1). Sepsis is the primary cause of mortality and morbidity in
pediatric oncology patients with febrile neutropenia (2). The rate of mortality due to
sepsis is 1.6-fold higher for oncology pediatric patients than it is for other pediatric
patients (3). Aminoglycoside antibiotics, such as gentamicin, in combination with other
broad-spectrum antibacterial agents play an important role in managing infectious
complications in these individuals and are used as second-line therapies when treating
Gram-negative bacterial infections and when resistance to ﬁrst-line agents develops (4).
Gentamicin has a narrow therapeutic window and displays large pharmacokinetic
variability. High levels of and prolonged exposure to gentamicin has been associated
with nephro- and ototoxicity (5, 6). Pediatric oncology patients often receive long
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courses of gentamicin on multiple occasions alongside chemotherapy, which further
increases the risk of toxicity.
Physiological changes (e.g., the presence of fever, augmented renal clearance,
decreased muscle mass, or malnutrition) in oncology patients and administration of
chemotherapy can alter a patient’s body composition and the pharmacokinetics of
gentamicin, increasing the difﬁculty of identifying the optimal dose (7–9). Increased
clearance (CL) and an increased volume of distribution (V) for gentamicin have been
seen in adults (7) and pediatric patients (8, 10) with cancer. Augmented renal clearance,
possibly due to systemic inﬂammation, has also been reported in febrile neutropenic
patients (11). However, when the CL of gentamicin was normalized by body surface
area, it decreased in those patients receiving prior nephrotoxic chemotherapy com-
pared to those who did not receive nephrotoxic chemotherapy (8).
The Australian Therapeutic Guidelines (12) recommend that for safety and efﬁcacy
reasons, aminoglycoside antibiotic doses should be adjusted on the basis of a com-
puterized method, such as Bayesian forecasting. While the log-linear regression method
is more commonly used (13), it may be more invasive, tedious, and reactive in nature
than Bayesian forecasting. The former requires at least 2 blood sample measurements
for predictions (14), whereas Bayesian forecasting may require only 1 sample, and it is
not able to give dosage predictions until a dose has ﬁrst been administered. In adults
with febrile neutropenia, a Bayesian approach has been shown to increase the number
of patients achieving the desired target exposure to gentamicin compared to the
number achieving the desired target obtained when the log-linear regression method
is used (15).
To be able to perform dosage individualization through Bayesian forecasting, a
population pharmacokinetic model which characterizes typical pharmacokinetic pa-
rameter values, between- and within-subject pharmacokinetic variability, and inﬂuen-
tial covariate factors associated with the drug of interest in the cohort receiving such
therapy ﬁrst needs to be developed. Few population pharmacokinetic models of
gentamicin have been developed in children between 2 and 18 years of age (16–18),
and to our knowledge, no models speciﬁcally characterizing pediatric oncology pa-
tients currently exist. Application of a relevant population model in a Bayesian fore-
casting program would likely improve the individualization of gentamicin dosing in
pediatric oncology patients (15, 19).
This study aimed to describe the population pharmacokinetics of gentamicin in
pediatric oncology patients with febrile neutropenia; evaluate the inﬂuences of cova-
riates, such as concomitant chemotherapy treatment; characterize pharmacokinetic
variability in this population; and externally evaluate the predictive performance of this
model as well as previously published models in a separate patient cohort.
RESULTS
Patients and data. Data from a total of 423 pediatric oncology patients (219 males
[52%]) with 2,422 gentamicin concentration-time data points were used for model
development. Eighty-eight percent of these patients had febrile neutropenia, and 12%
had fever-free neutropenia. The patients’ median postnatal age was 5.18 years (range,
0.2 to 18.2 years), the patients’ median weight was 19.4 kg (range, 4.8 to 102.8 kg), and
the patients’ median fat-free mass (FFM) was 15.7 kg (range, 3.4 to 72.6 kg). Seventy-
three patients (17%) were younger than 2 years of age, 247 patients (59%) were 2 to 10
years old, and 103 patients (24%) were older than 10 years of age. Gentamicin
concentration measurements ranged from 0.3 to 62.5 mg/liter, with sampling times
after the end of the infusion ranging from 0.5 to 36.0 h. A total of 372 (15%) gentamicin
measurements were below the lower limit of quantitation (LLOQ) at an average of 15
h after dosing. For model evaluation, data from 52 pediatric oncology patients (22
males [42%]) with 174 gentamicin concentration-time points were used. The patients’
median postnatal age was 7.9 years (range, 0.7 to 16.8 years), the patients’ median
weight was 22.2 kg (range, 6.2 to 121.0 kg), and the patients’ median FFM was 20.5 kg
(range, 5.3 to 62.2 kg). Eight patients (15%) were younger than 2 years of age, 33
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patients (64%) were 2 to 10 years old, and 11 patients (21%) were older than 10 years
of age. Gentamicin concentration measurements ranged from 0.5 to 30.8 mg/liter, with
samples being taken from 0.75 to 34.3 h after the end of the infusion. A total of 16 (9%)
gentamicin measurements were below the LLOQ. Key patient demographic character-
istics, laboratory values, and gentamicin dosing information are summarized in Table 1.
Pharmacokinetic model. A two-compartmental model with ﬁrst-order elimination
best described the data (change in the objective function value [ΔOFV]  332.7
compared to a one-compartmental model). The typical CL estimated was 5.77 liters/
h/70 kg, and the apparent volume of distribution of the central compartment (V1) was
17.4 liters/70 kg. Between-subject variability (BSV), including a correlation between CL
and V1 (ΔOFV  156.5) and between-occasion variability (BOV) on CL (ΔOFV 
516.4), was estimated for CL, V1, and the apparent volume of distribution of the
peripheral compartment (V2).
Inclusion of the effect of maturation of the glomerular ﬁltration rate (GFRmat) on CL
and the effect of either FFM, body weight, or normal fat mass (NFM) on V1, intercom-
partmental clearance (Q), and V2 improved the ﬁt and increased the explained vari-
ability. The use of any body size descriptor (body weight, NFM, or FFM) in the GFRmat
equation and for V1, Q, and V2 resulted in a signiﬁcant drop in the OFV (ΔOFV406.6,
ΔOFV  403.1, and ΔOFV  408.3, respectively) (see Table S1 in the supplemental
material). However, according to the Akaike information criterion (AIC), FFM ﬁt the data
best compared to body weight and NFM. Addition of GFRmat increased the explained
parameter variability (EPV) on CL (change in EPV [ΔEPV] 1.15 liters/h), as did inclusion
of FFM on V1 (ΔEPV  12.67 liters) (Table S1). In addition to GFRmat, inclusion of an
association between the serum creatinine concentration (Scr) measurement and gen-
tamicin CL using a power model (ΔOFV324.2) further signiﬁcantly improved the ﬁt.
Inclusion of Scr increased EPV on CL compared to the previous model that included
only GFRmat (Table S1). In subsequent steps, inclusion of the effect of the use of
TABLE 1 Demographic and clinical information for all patients included in model building and evaluation analysis
Patient characteristic
Values
Model-building data
(n  423)
Model evaluation data
(n  52)
Median (range):
Total body wt (kg) 19.4 (4.8–102.8) 22.2 (6.22–121)
FFM (kg) 15.7 (3.4–72.6) 20.5 (5.25–62.2)
Postnatal age (yr) 5.18 (0.2–18.2) 7.86 (0.69–16.8)
Postmenstrual age (wk) 309 (50.9–985) 450 (76.0–916)
Ht (cm) 110.2 (48.8–182.3) 127 (67.5–175)
No. (%) of patients aged (yr):
2 73 (17.3) 8 (15.4)
2–10 247 (58.4) 33 (63.5)
10 103 (24.3) 11 (21.1)
No. (%) male/female patients 219 (52)/204 (48) 22 (42)/30 (58)
Median (range):
Serum creatinine concn (mol/liter)
Below the lowest reportable limita 33.0 (21.0–204.0) 34.0 (21.5–359)
Above the lowest reportable limit 42.0 (30.0–204.0) 43.0 (30.0–359)
Creatinine clearance (ml/min/1.73 m2)b 126 (11.5–225.2) 132 (9.08–186)
Gentamicin dosing regimen (mg/kg) 7.35 (0.80–15.0) 7.33 (1.98–10.8)
Time of sampling after dosing (h) 6.50 (0.5–36.0) 3.34 (0.75–34.4)
No. of gentamicin concn 2,422 174
No. (%) of gentamicin concn below limit of quantiﬁcation 372 (15) 16 (9)
No. (%) of patients who received nephrotoxic drugs (cisplatin and carboplatin) 101 (24) 6 (11.5)
aSerum creatinine concentration below the lowest reportable limit set to an expected creatinine concentration physiological mean (42).
bCreatinine clearance calculated using the formula of Schwartz et al. (45), with the serum concentration below the lowest reportable limit being set to an expected
physiological mean creatinine concentration (42).
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nephrotoxic drugs and body temperature on gentamicin CL resulted in nonsigniﬁcant
improvements (ΔOFV  2.80 and 1.30, respectively). Typical pharmacokinetic pa-
rameter estimates for the base and ﬁnal models are shown in Table 2.
Model selection and internal model evaluation. Visual predictive check (VPC)
plots associated with the ﬁnal model indicated good agreement between the observed
and predicted data (Fig. 1). VPC, normalized prediction distribution errors (npde), and
goodness-of-ﬁt plots associated with the ﬁnal model are shown in Fig. 1.
Results from the nonparametric bootstrap were in agreement with the population
pharmacokinetic parameters in the ﬁnal model with narrow 95% conﬁdence intervals
(Table 2). As the eta shrinkage on CL, V1, and V2 was relatively high in the ﬁnal model
(43%, 58%, and 66%, respectively), the diagnostic use of goodness-of-ﬁt plots has been
limited (20), and these have not been presented.
External evaluation of the ﬁnal model and models published in the literature.
From the literature search, only three population pharmacokinetic models of gentami-
cin developed in pediatric populations were identiﬁed (Table 3) (16, 17, 21). These
models, together with the ﬁnal model from this study, were tested regarding their
predictive performance with the external data set. Observed versus population pre-
dicted concentration-time plots and VPC plots obtained from all four models generated
during external evaluation are displayed in Fig. S1 and 2, respectively. Of the four
models evaluated, the ﬁnal population model developed in this study was the least
biased, with a mean relative prediction error (MRPE) of 3.40%, and the most precise,
with a root mean square error (RMSE) of 46.0%, compared to the other models tested
(Fig. 2).
DISCUSSION
This study developed and externally evaluated a population pharmacokinetic
model of gentamicin in pediatric oncology patients that could be used to improve
adjustment of the dosage of this drug in this cohort in the future. The ﬁnal model
included an effect of renal function on CL and an effect of FFM on all pharmacokinetic
parameters. Prior use of nephrotoxic agents, cisplatin and carboplatin, was not identi-
ﬁed as having a signiﬁcant inﬂuence on the CL of gentamicin, after taking into
consideration maturation changes in renal function and the potential function impair-
ment observed given a patient’s Scr. FFM was identiﬁed to be the best descriptor to
model the inﬂuence of body size on gentamicin CL, V1, Q, and V2. The ﬁnal model
displayed good predictive performance, when it was applied to a new data set not used
for model development.
Selection of a two-compartment model with ﬁrst-order elimination to describe the
disposition of gentamicin in this study is in agreement with the models selected in a
number of studies performed in nononcology children, neonates, and adults included
in a recent review (22). Only one population pharmacokinetic model of gentamicin has
previously been developed in children who were of an age similar to that of the
children included in this study (18). This previous study involved nononcology children
(median age, 2.4 years) who received gentamicin intramuscularly (18). The typical
gentamicin apparent CL (CL/F) in these children (7.21 liters/h/70 kg for a patient with
an average Scr of 33.0 mol/liter) was higher than that estimated in this study based
on intravenous administration (5.77 liters/h/70 kg for a patient with an average Scr of
37.4 mol/liter). Two studies have been performed in pediatric oncology patients, but
they used noncompartmental analysis methods (8, 10). In the ﬁrst study (8), typical CL
values of 9.33 liters/h/70 kg and 10.3 liters/h/70 kg were reported in pediatric patients
receiving and not receiving chemotherapy, respectively. In the second study (10), a
typical CL of 8.10 liters/h/70 kg was reported. Comparison of the CL values of genta-
micin obtained in this study with the values published in the literature is difﬁcult
because most previous studies were primarily based on neonates or infants and
involved different analysis techniques. The typical V1 estimated in this study (21.6
liters/70 kg) was similar to that described in other reports; however, it was lower than
that reported previously in nononcology children (24.5 liters/70 kg) and preterm
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neonates (31.1 liters/70 kg) and higher than that reported in term neonates (19.3
liters/70 kg) (22).
The ﬁnal model included an effect of body size in terms of FFM on all pharmaco-
kinetic parameters. When the ﬁnal model was applied to an external data set, it
predicted gentamicin concentrations more accurately and precisely than a model using
NFM on all pharmacokinetic parameters. A recent review of population pharmacoki-
netic models of gentamicin found that total body weight was the most common
covariate included as a body size descriptor on CL and V1 (22). Considering that before
2015 no FFM equation for pediatrics was available (23), the inclusion of FFM in models
for pediatric populations was limited. This study found that FFM explained more
variability between subjects than other body size descriptors, possibly due to the fact
that gentamicin is highly hydrophilic and mainly distributes into muscle mass or lean
body weight rather than fat. One study of gentamicin in elderly patients included the
effect of FFM on V1 (24), and another reported that FFM improved the prediction of GFR
in pediatric patients (25).
An equation describing changes in renal function over time due to organ matura-
tion (GFRmat) was utilized here. This equation was originally developed from a large
study involving 923 patients ranging from premature neonates to young adults, of
which most had normal renal function and only 5% were known oncology patients (25).
We found that additional inclusion of the effect of Scr on CL after consideration of renal
function maturation through GFRmat further improved the model ﬁt. An accurate
bedside estimate of renal function does not exist for young children, and Scr is not
generally considered to be a good marker to describe renal function maturation in
FIG 1 (a) Visual predictive check plot based on 500 simulations associated with the ﬁnal population
pharmacokinetic model. Gray dots, observed data; red line, the median and 95th and 5th percentiles of
the observed data; black dashed line, median and 95th and 5th percentiles of the simulated data; gray
areas, 95% conﬁdence interval of the simulated data; (b) normalized prediction distribution errors based
on 1,000 simulations associated with the ﬁnal population pharmacokinetic model versus time after dose
(black dots, observed data; gray area, 95% conﬁdence interval of the simulated data); (c) observed versus
population predicted gentamicin serum concentrations (black dots, observed data; black line is the line
of identity and red line is a smooth); (d) conditional weighted residuals versus time after dose associated
with the ﬁnal population pharmacokinetic model (black dots, observed data; black line is the line of
identity and red line is a smooth).
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pediatric patients, especially in oncology patients, due to the lack of muscle mass (26),
though in this study, for patients with an Scr of 30 mol/liter, Scr appeared to be a
marker of renal dysfunction, which is not accounted for in the GFR renal maturation
equation. According to our ﬁnal model, a 2-fold increase in Scr in patients with an Scr
of30 mol/liter led to a 32% decrease in gentamicin CL. Inclusion of Scr in the model
was further supported by an increase in EPV and a signiﬁcant drop in OFV. A limitation
of using Scr in this study was that 52% of Scr measurements were30 mol/liter; thus,
the model does not account for renal dysfunction in patients with an Scr of 30
mol/liter. Inclusion of covariates resulted in a large decrease in BSV in CL and V1
between the base model and the ﬁnal model, namely, 28% and 29%, respectively (Table
2). Both BSV and BOV were below 21% for CL; however, BOV was slighter higher than
BSV, which may have been due to underlying changes in the patient’s physiological
condition with cancer treatment over time.
The usage of cisplatin and carboplatin was not found to have a signiﬁcant effect on
gentamicin CL. It should be noted, however, that only 24% of patients received these
drugs in the 6-month period prior to gentamicin administration, the window consid-
ered during modeling. This window may be too wide or narrow for examination (27,
FIG 2 Visual predictive check plot based on 500 simulations associated with this study’s ﬁnal population pharmacokinetic
model and three other published population pharmacokinetic models of gentamicin in children generated during external
evaluation. Gray dots, observed data; red lines, median and 95th and 5th percentiles of the observed data; black dashed lines,
median and 95th and 5th percentiles of simulated data; gray areas, 95% conﬁdence interval of simulated data. The predictive
performance for each model is presented numerically with the relative root mean square error (RMSE; in percent) and the
mean relative prediction error (MRPE; in percent). M1 to M3, models 1 to 3 from previous studies (see references 16, 21, and
17 respectively).
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28), and cumulative lifetime use was not assessed. Moreover, inclusion of patient Scr
values within the model may already account for any potential nephrotoxicity caused
by these agents. Further attempts were made to assess the inﬂuence of cumulative
doses of cisplatin and carboplatin and the timing of their coadministration on genta-
micin CL, but no signiﬁcant relationships were identiﬁed.
One previous study reported that body temperature can inﬂuence gentamicin CL in
pediatric patients (18). Here, the inﬂuence of body temperature on gentamicin CL did
not show signiﬁcance. Body temperature may not have been a suitable marker for
critically ill patients here, possibly due to the potential use of antipyretics, resulting in
a median body temperature of 36.6°C during gentamicin therapy. Information on
antipyretic usage was not collected in this study; however, antipyretics are part of the
standard treatment for febrile neutropenia.
Previous pharmacokinetic studies using noncompartmental pharmacokinetic anal-
ysis suggested gentamicin starting doses of between 7.5 and 10.8 mg/kg of body
weight for pediatric oncology patients (8, 10, 29). While exposure targets have not been
fully elucidated in this population, guidelines typically recommend that an area under
the concentration-time curve from time zero to 24 h (AUC24)-to-bacterial MIC ratio
(AUC24/MIC) of between 80 and 100 and/or a maximum concentration (Cmax)-to-MIC
ratio (Cmax/MIC) of greater than 10 be targeted (30, 31). These targets were obtained
from clinical studies performed in adults and consider several different microorganisms
(32, 33). Given these targets and the estimated population CL in this study, an initial
dose of 8.0 mg/kg would be required for a typical patient in this study to achieve this
target, which is in agreement with previous dose recommendations in this population.
External model evaluation showed that previously published pediatric models
overpredicted exposure compared to that predicted by our model. This is not unex-
pected, as the previous models, even though only models including pediatric patients
were considered, were based on different patient cohorts in terms of age, disease state,
and medication usage. In addition, two out of three previous models evaluated in this
study (16, 21) did not scale CL using an allometric weight with an exponent of 0.75. This
may partly explain the poor performance of these models in predicting gentamicin
concentrations in our pediatric oncology patients (34). This reinforces the suggestion that
a population pharmacokinetic model should not be applied to individuals with character-
istics too far beyond the characteristics of the cohort in which it was developed.
On the basis of a visual and numerical assessment, the ﬁnal model presented in this
study displayed good predictive performance and should be clinically useful in the
pediatric oncology setting. In addition, all PK parameters were estimated with relative
standard errors (RSE) of less than 20%.
This study had limitations in terms of the sparse number of samples per patient per
dose collected from the therapeutic drug monitoring (TDM) data available. This is
common in special populations, such as pediatric populations (35), and may have led
to the higher eta shrinkage and limited the use of diagnostic plots of individual
parameter estimates and covariates (20). Furthermore, this study involved retrospective
data collection, which relies on the accuracy of written medical charts.
After implementation of the model in a Bayesian forecasting program, future studies
should focus on evaluating its clinical applicability to personalize gentamicin dosing
regimens, ability to reduce the frequency of blood sampling during TDM, and capacity to
improve target attainment compared to current practice in pediatric oncology patients (10).
Conclusions. To the best of our knowledge, the model described in this study
presents the ﬁrst population pharmacokinetic model for gentamicin in pediatric on-
cology patients with febrile neutropenia. This model was developed on the basis of
physiologically plausible covariate parameterization informed by principles of allomet-
ric scaling, maturation of the glomerular ﬁltration rate, and standardization for the
age-expected serum creatinine concentration. The serum creatinine concentration
measurement in this model accounted for renal dysfunction not explained by matu-
ration. The model developed displayed a predictive performance superior to that of a
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very limited number of models currently describing gentamicin pharmacokinetics in
pediatric patients. This model is now available to be implemented in a Bayesian
forecasting program, such as TDMx (http://www.tdmx.eu/) (36), for initial dose individ-
ualization and adaptive dose adjustment of gentamicin in pediatric oncology patients,
to improve achievement of individualized exposure targets.
MATERIALS AND METHODS
Patients and data. Data for model building and model evaluation were collected retrospectively
from the medical records of pediatric oncology patients at The Lady Cilento Children’s Hospital (formerly
known as the Royal Children’s Hospital), Brisbane, Australia. These patients received gentamicin and had
drug concentrations measured during routine therapeutic drug monitoring (TDM) between 2008 and
2013 (model-building data set) and 2014 and 2015 (model evaluation data set). Ethics approval for this
study was obtained from the University of Queensland Human Research Ethics Unit (approval number:
2012001308) and the Children’s Health Queensland Hospital and Health Service Human Research Ethics
Committee (approval number HREC/12/QRCH/162).
Information on gentamicin dosing regimens, the timing of dose administration, gentamicin serum
drug concentrations, and the times of sample collection for drug measurement, along with the patients’
age, sex, total body weight, height, Scr, and body temperature readings, were recorded. In addition,
information on the date, administration time, and dose of speciﬁc nephrotoxic drugs (cisplatin and
carboplatin) that the patients had received within the 6 months preceding gentamicin usage were
collected.
Gentamicin treatment and blood sampling. Pediatric oncology patients with a neutrophil count
of 1.0 cells/mm3 who developed a fever (a temperature of 38.5°C for at least 1 h or 38.0°C for at
least 2 h) and who were considered critically ill or at high risk received gentamicin, in addition to
empirical broad-spectrum penicillin-based therapy. Gentamicin was also added as directed treatment if
cultures were conﬁrmed to be positive for Gram-negative bacteria. Gentamicin was given as a 30-min
infusion once daily and was initiated at a dose of 7.5 mg/kg for patients under 10 years of age and 6
mg/kg for patients over 10 years of age according to local hospital guidelines. Blood samples for
measurement of gentamicin serum concentrations during TDM were generally taken at 2 h and 6 to 12
h postinfusion. In addition, on the basis of clinical judgment, samples were sometimes taken before a
subsequent dose (for determination of trough levels).
Gentamicin assay. The gentamicin concentration in serum was measured using a ﬂuorescence
polarization immunoassay method at the Pathology Queensland Central Laboratory, Brisbane, Australia.
Different immunoassays were applied over time. From 2008 to August 2011, a Beckman Coulter
particle-enhanced turbidimetric inhibition immunoassay (PETINIA) run on a Beckman Coulter DXC800
analyzer was used. From August 2011 to November 2011, an Abbott chemiluminescent magnetic
microparticle immunoassay run on an Abbot Architect i1000 immunoassay analyzer was used. From
November 2011 to December 2012, a Beckman Coulter cloned enzyme donor immunoassay run on a
Beckman Coulter DXC800 analyzer was used. From December 2012 onwards, a Beckman Coulter PETINIA
run on a Beckman Coulter DXC800 analyzer was used. The lower limit of quantiﬁcation (LLOQ) varied
from 0.3 to 0.6 mg/liter across the immunoassay methods. Within- and between-assay coefﬁcients of
variation were below 10% for all immunoassays employed.
Population pharmacokinetic analysis. (i) Software. Population modeling was performed using
NONMEM software (version 7.3; Icon Development Solutions, Ellicott City, MD, USA) (37) with an Intel
FORTRAN compiler and Perl-speaks-NONMEM (PsN; version 3.5.3) (38). Typical population pharmacoki-
netic parameters of gentamicin as well as between-subject variability (BSV), between-occasion variability
(BOV), and residual unexplained variability (RUV) were estimated via the ﬁrst-order conditional estimation
method with interaction (FOCEI). Xpose (version 4.4.0; http://xpose.sourceforge.net) and R studio
(version 3.1; http://www.r-project.org./) software were used for data exploration and visualization.
(ii) Model development. First, a base model was developed by testing one-, two-, and three-
compartment structural disposition models with ﬁrst-order elimination. Pharmacokinetic parameter
values were assumed to be log-normally distributed. BSV was modeled using an exponential model
(equation 1) and was initially applied to all pharmacokinetic parameters, and the parameters were
removed if they were not supported. BOV was modeled using an additional random effects parameter
(equation 2), which was tested one by one on CL and V.
Pi TVP e
i,P (1)
Pij TVP e
i,P	i,P (2)
where TVP is the typical population parameter estimate and Pi is the parameter estimate for individual
i; i,P is a symmetrically distributed random variable with a mean of zero and a variance of 
2BSV_P, where
the square root of the variance represents the reported BSV; and Pij is the parameter value for individual
i on the jth occasion, 	i,P is the within-patient random effect, which is independent and normally
distributed with a mean of zero and a variance of 
2BOV_P. Proportional, additive, and combined models
and different error models for the concentrations measured using different assays were compared during
model building to describe RUV. Gentamicin drug concentrations reported as being below the LLOQ
were replaced by LLOQ/2 values (39).
Clinical factors investigated for an inﬂuence on the pharmacokinetics of gentamicin included the
patient’s renal function (described by body size and age), Scr measurements, sex, use of nephrotoxic
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drugs, and body temperature. After a structural base model was established, potential covariates were
screened initially via graphical exploration, considering shrinkage (20). Covariate model building was in
the ﬁrst instance based on physiologically plausible covariate parameterization informed by principles of
allometric scaling, maturation of the glomerular ﬁltration rate, and standardization for the age-expected
serum creatinine concentration.
The impact of changes in renal function due to maturation on gentamicin clearance was included
using the glomerular ﬁltration rate prediction model developed by Rhodin et al. (GFRmat; in milliliters per
minute; see equation 3) (25). Three descriptors of body size were tested in the GFRmat equation: total
body weight, normal fat mass (NFM) (40), and fat-free mass (FFM) (23). Both, FFM and the fraction of fat
mass were used within the NFM calculation, with the fraction of fat mass being estimated. Allometric
scaling (34, 41) using each of these three descriptors of body size (total body weight, NFM, and FFM) was
applied to all other clearance and distribution parameters according to equation 4.
GFRmat  size descriptori70 0.75 PMA3.3355.43.33 PMA3.33  112 (3)
Pi TVP  size descriptori70 allometric exponent (4)
where Pi is the parameter of interest, TVP is the typical population parameter value, and size descriptori
represents either body weight, FFM, or NFM (in kilograms) for individual i, which was standardized to 70
kg, to ease comparison to adult values. PMA is postmenstrual age (in weeks), calculated for each child
by addition of 40 weeks, representing a typical gestation period, to their postnatal age.
Afterwards, Scr and body temperature were subsequently tested using a linear, exponential, and/or
power model. An inverse relationship between Scr and CL was examined, with Scr being standardized
to the mean expected creatinine concentration for a person of the relevant age and sex (42). For patients
who had an Scr measurement below the lowest reportable limit (30 mol/liter), this value was ﬁxed to
the mean expected physiological creatinine concentration for a person of the relevant age and sex (42).
The categorical covariates sex and use of cisplatin and/or carboplatin within 6 months prior to the
gentamicin observation were tested by estimating the typical parameter value for the most common
category and then obtaining the fractional difference in the parameter value for the second category
compared to that for the ﬁrst category.
(iii) Model selection and internal model evaluation. For nested models, the difference between a
pair of objective function values (OFV) for two models approximates the chi-square (2) statistic, which
can be tested for signiﬁcance (21, 0.05  3.84). The Akaike information criterion (AIC) was used for
nonnested models. Further support for model selection was obtained by evaluating the difference in the
magnitude of the change in the explained parameter variability (ΔEPV) after covariate inclusion com-
pared to that in the base model (43). Basic goodness-of-ﬁt plots for observations versus population
predictions and conditional weighted residuals versus time after dose were examined for internal model
evaluation. Model predictive performance was assessed by generating visual predictive check (VPC) plots
based on 500 simulations. Plot of normalized prediction distribution errors (npde) versus time after
dosing based on 1,000 simulations were also generated and evaluated. The precision of the model
parameters was obtained from the relative standard errors and conﬁrmed through nonparametric
bootstrapping of the ﬁnal model with 1,000 replicates.
(iv) External evaluation of the ﬁnal model and models published in the literature. The model
evaluation data set was used to externally evaluate the predictive performance of the ﬁnal model as well
as any previous population models of gentamicin published in the literature that were based on pediatric
patients. A literature search was conducted in September 2016 using the PubMed and EMBASE databases
with a restriction to English language publications to identify previously published population pharma-
cokinetic models. The following keywords were used during the search: gentamicin, pediatric, pharma-
cokinetics, and population pharmacokinetics. Models were included if they were developed in a pediatric
population with a postnatal age of 5 months using a compartmental approach and were excluded if
they did not provide enough information to be fully reproducible.
Each selected population pharmacokinetic model was implemented using NONMEM software, as
stated above. Gentamicin concentrations were predicted using information on the gentamicin dosing
regimen, time of sample collection for drug measurement, and relevant patient covariate values
recorded for the evaluation data set, with pharmacokinetic parameter values and covariate relationships
set being those determined in the ﬁnal model and in the previous publications. The predictive
performance of each selected population pharmacokinetic model was assessed visually (predicted
concentration [Cpred] versus observed concentration [Cobs] plots and VPC plots) and numerically. Bias and
precision were calculated using the relative root mean square error (RMSE; in percent) (equation 5) and
mean relative prediction error (MRPE; in percent) (equation 6) (44):
RMSE 1
Ni1
N Cpred CobsCobs i
2
 100 (5)
MRPE
1
Ni1
N Cpred CobsCobs i 100 (6)
where N is the number of concentration measurements in the sample.
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